ArticleDrug design, development and therapy2026
Psychiatric, Cardiovascular and Skeletal Risks of Codeine versus Oxycodone in Hip Osteoarthritis: A Population-Based Cohort Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative risk of psychiatric comorbidities associated with codeine and tramadol in patients with hip osteoarthritis: a nationwide population-based cohort study.Journal of global health · 2026Article
- Methodological Concerns Regarding Codeine and Oxycodone Safety Comparisons in Hip Osteoarthritis [Letter].Drug design, development and therapy · 2026Article
- Methodological Concerns Regarding Codeine and Oxycodone Safety Comparisons in Hip Osteoarthritis [Response to Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Hip osteoarthritis (OA) induces chronic pain and disability in aging populations. Opioids are increasingly prescribed for refractory hip OA pain; however, comparative safety data are limited. This study aimed to compare the psychiatric, cardiovascular and skeletal outcomes between codeine and oxycodone in patients with hip OA. Methods: A population-based retrospective cohort using Korean Health Insurance Review and Assessment Service (HIRA) claims data was performed in hip OA (M16) patients who initiated codeine or oxycodone. Propensity score matching (PSM) was applied with sensitivity analyses performed using inverse probability of treatment weighting (IPTW). Outcomes included composite psychiatric outcomes (depression, anxiety, bipolar disorder, sleep disorders, and schizophrenia), major adverse cardiovascular outcomes (MACE; myocardial infarction, stroke, cardiovascular death/arrest, heart failure hospitalization), and fractures. Hazard ratios (HR) with 95% confidence intervals (CIs) were estimated using Cox proportional hazard models. Results: A total of 16,162 patients were included in the cohort after 1:1 PSM. Codeine was associated with a higher risk of psychiatric disorders (HR 1.11, 95% CI 1.04-1.19), particularly anxiety (HR 1.14, 95% CI 1.03-1.26) and sleep disorders (HR 1.15, 95% CI 1.02-1.30). Risks of MACE (HR 1.02, 95% CI 0.92-1.14) and death (HR 1.03, 95% CI 0.92-1.14) were comparable between groups. Codeine was associated with a higher risk of non-femoral fractures (HR 1.10, 95% CI 1.04-1.16). Subgroup analyses revealed differentiated risks across age, sex, comorbidities, and concomitant medications. Conclusion: Codeine use in patients with hip osteoarthritis was associated with a higher risk of psychiatric disorders and distinct fracture patterns. The observed risks varied according to patient characteristics, comorbidities, and concomitant medications, emphasizing the need for individualized opioid prescribing strategies that incorporate psychiatric monitoring, fracture risk assessment, and patient-specific factors. Further controlled studies integrating clinical, lifestyle, and genetic data are warranted to confirm these findings and refine personalized opioid therapy in hip osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.